-- IT/Informatics:
Ingenuity Systems - Path Designer
Ingenuity Systems introduces Path Designer Analysis 6, the publishing
tool within IPA 6 that transforms networks and pathways into
publication-quality graphics rich with color, customized text,
biological icons, and organelles. Path Designer's interactive images
link directly to Ingenuity's knowledge base. This easy-to-use graphics
package completes the research workflow -- from data analysis to
publication of results -- within a single software solution.
www.ingenuity.com
-- Instrumentation:
Fluidigm Corporation - BioMark Real Time PCR System
BioMark™ Real Time PCR System -- Bridging the gap between discovery
and clinically useful biomarkers requires next-generation technology --
tools that deliver radical new efficiency for the analysis of nucleic
acids. The BioMark™ Real Time PCR System meets this challenge
through integrated fluidic circuits (IFCs), which represent a
fundamental advance in simplicity and throughput over microwell plates.
www.fluidigm.com
-- Drug Discovery Tools:
There was a tie
Enamine LLC - Pharmacological Diversity Set
Enamine introduces their new Pharmacological Diversity Set (PDS) which
is a unique alternative to common Structural Diversity Sets (SDS).
While SDS was designed to offer maximum diversity based on chemical
structures alone, PDS has been designed to offer clustered diversity
sets with biological activity in mind. This unique set was designed by
evaluating over 3000 pharmacological activities from the literature for
each compound in our Drug-Like Collection. www.enamine.net
Thermo Scientific/Dharmacon Products - Accell™ siRNA Reagents &
SMARTvector shRNA Lentiviral
Accell™ siRNA Reagents delivers knockdown in every cell type tested
to date, including primary, neuronal, and stem cells, without a
transfection reagent or viral vector. Accell siRNA has a 2-step
protocol that requires no optimization, yet provides highly specific
silencing without non-specific delivery effects that cause toxicity and
false phenotypes. www.thermo.com/dharmacon
SMARTvector shRNA Lentiviral platform merges multiple design
innovations that improve silencing functionality and specificity,
including a novel microRNA-based expression system and specialized
selection algorithm. Delivered by high-titer lentiviral particles,
functional long-term knockdown can be achieved in a broad range of cell
types. www.thermo.com/dharmacon
-- Molecular Diagnostics
Decision Biomarkers Inc. - MAX BIOCHIP
Decision Biomarkers launches AVANTRA™ biomarker workstation along
with its innovative MAX BIOCHIP™ 8-plex cytokine immunoassay. The
system's ease-of-use enables users to generate data in real-time by
virtually anyone, anywhere in drug development and clinical trials
accelerating decision making and improving project productivity.
www.decisionbiomarkers.com
-- Cells and Assays
Stem Cell Technologies, Inc. - mTeSR1
mTeSR™1 is a novel, defined medium designed to maintain human
embryonic and induced pluripotent stem cells in the undifferentiated
state without the use of feeders. This product provides consistent
culture conditions for pluripotent stem cells and considerably
simplifies the process of maintaining these clinically important cells
undifferentiated. www.stemcell.com
About the Molecular Medicine Tri-Conference
The Molecular Medicine Tri-Conference is the largest annual West Coast
biotech conference, and brings together over 2,800 pharmaceutical and
biotech leaders from over 40 countries. This year's event featured over 200
presentations, 150 exhibit booths, 75 scientific posters, 3 plenary
keynotes, and scientific short courses including the expanded Biotech
Pharma Partnership. For more information, please visit
www.Tri-Conference.com.
About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (CHI) is the preeminent life science network
for leading researchers and business experts from top pharmaceutical,
biotech and academic organizations. CHI's portfolio of products includes
Cambridge Healthtech Institute Conferences, Insight Pharma Reports,
Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge
Healthtech's Media Group, which includes numerous e-newsletters as well as
Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality
information sources that provide valuable new insights and competing points
of view while offering balanced coverage of the latest developments. Basic
research related to commercial implications is covered, with heavy emphasis
placed on end-user insights into new products and technology as well as
coverage on the strategy behind the business.
Contact Information: Media Contact: Cambridge Healthtech Institute Tracey Fielding Marketing Communications Manager 781-972-5429